Novartis Ag (NVS) closed at $163.26 on November 10, 2026, down 0.3% from the previous close, on volume of 1,747,036 shares (30-day average 1,994,835).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 29, 2026 | Put Spread | 20-Nov-26155 : 160 P | 5,602 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Novartis AG (NOVN) Gets a Hold from Berenberg Bank
TipRanks (Wed, 11-Nov 2:35 AM ET)
Novartis releases long-term data for ianalumab in Sjögren’s disease
Seeking Alpha News (Tue, 10-Nov 2:07 PM ET)
Novartis AG (NOVN) Gets a Sell from Deutsche Bank
TipRanks (Tue, 10-Nov 5:05 AM ET)
Novartis AG (NOVN) Gets a Hold from Barclays
TipRanks (Mon, 9-Nov 3:55 AM ET)
Jefferies Keeps Their Hold Rating on Novartis AG (NOVN)
TipRanks (Mon, 9-Nov 2:25 AM ET)
Novartis is said to be abandoning Ionis heart drug after late-stage trial setback
Seeking Alpha News (Sat, 7-Nov 11:36 AM ET)
Citi Sticks to Their Buy Rating for Novartis AG (NOVN)
TipRanks (Fri, 6-Nov 2:16 AM ET)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
PRNewswire (Thu, 15-Oct 10:02 AM ET)
Big Pharma Setbacks Create a New Wave of Rebound Plays
Globe Newswire (Thu, 10-Sep 2:12 PM ET)
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
Globe Newswire (Thu, 10-Sep 8:30 AM ET)
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Novartis Ag trades on the NYSE stock market under the symbol NVS.
As of November 11, 2026, NVS stock price declined to $159.92 with 1,208,843 million shares trading.
NVS has a beta of 0.07, meaning it tends to be less sensitive to market movements. NVS has a correlation of 0.00 to the broad based SPY ETF.
NVS has a market cap of $302.03 billion. This is considered a Mega Cap stock.
Last quarter Novartis Ag reported $15 billion in Revenue and $2.46 earnings per share. This fell short of revenue expectation by $-35 million and exceeded earnings estimates by $.22.
In the last 3 years, NVS traded as high as $170.46 and as low as $92.35.
The top ETF exchange traded funds that NVS belongs to (by Net Assets): DFIV, DFAI, DFIC, AVDE, DIHP.
NVS has outperformed the market in the last year with a price return of +29.5% while the SPY ETF gained +12.7%. NVS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +2.0% and +2.0%, respectively, while the SPY returned -1.4% and -1.2%, respectively.
NVS support price is $160.47 and resistance is $166.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVS shares will trade within this expected range on the day.
